title: Bone marrow expression of poly(ADP-ribose) polymerase underlies diabetic neuropathy via hematopoietic-neuronal cell fusion.
abstract: Diabetic neuropathy is the most common diabetic complication. The pathogenetic pathways include oxidative stress, advanced glycation end product (AGE) formation, protein kinase C, and NF-κB activation, as well as increased polyol flux. These metabolic perturbations affect neurons, Schwann cells, and vasa nervorum, which are held to be the primary cell types involved. We hypothesize that diabetes induces the appearance of abnormal bone marrow-derived cells (BMDCs) that fuse with neurons in the dorsal root ganglia (DRG) of mice, leading to diabetic neuropathy. Neuronal poly(ADP-ribose) polymerase-1 (PARP-1) activation in diabetes is known to generate free radical and oxidant-induced injury and poly(ADP-ribose) polymer formation, resulting in neuronal death and dysfunction, culminating in neuropathy. We further hypothesize that BM-specific PARP expression plays a determining role in disease pathogenesis. Here we show that bone marrow transplantation (BMT) of PARP-knockout (PARPKO) cells to wild-type mice protects against, whereas BMT of wild-type cells to PARPKO mice, which are normally "neuropathy-resistant," confers susceptibility to, diabetic neuropathy. The pathogenetic process involving hyperglycemia, BMDCs, and BMDC-neuron fusion can be recapitulated in vitro. Incubation in high, but not low, glucose confers fusogenicity to BMDCs, which are characterized by proinsulin (PI) and TNF-α coexpression; coincubation of isolated DRG neurons with PI-BMDCs in high glucose leads to spontaneous fusion between the 2 cell types, while the presence of a PARP inhibitor or use of PARPKO BMDCs in the incubation protects against BMDC-neuron fusion. These complementary in vivo and in vitro experiments indicate that BMDC-PARP expression promotes diabetic neuropathy via BMDC-neuron fusion.
authors: Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
authors: Tomoya
authors: T
authors: Terashima
authors: Hideto
authors: H
authors: Kojima
authors: Lawrence
authors: L
authors: Chan
mesh_terms: D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology* / Q000187:drug effects / Q000201:enzymology; D016026:Bone Marrow Transplantation; D002459:Cell Fusion; D002478:Cells, Cultured; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000201:enzymology / Q000473:pathology; D003929:Diabetic Neuropathies / Q000201:enzymology / Q000209:etiology / Q000473:pathology; D005260:Female; D005727:Ganglia, Spinal / Q000166:cytology / Q000201:enzymology; D005947:Glucose / Q000494:pharmacology; D007328:Insulin / Q000235:genetics; D007546:Isoquinolines; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009431:Neural Conduction / Q000502:physiology; D009619:Nociceptors / Q000166:cytology* / Q000187:drug effects / Q000201:enzymology; D018384:Oxidative Stress / Q000502:physiology; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases / Q000235:genetics* / Q000378:metabolism; D011123:Polyploidy; D011804:Quinolines / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics; D014998:Y Chromosome / Q000235:genetics
chemical_list: D007328:Insulin; D007546:Isoquinolines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011804:Quinolines; D014409:Tumor Necrosis Factor-alpha; C095653:1,5-dihydroxyisoquinoline; D011065:Poly(ADP-ribose) Polymerases; D005947:Glucose